🚀 VC round data is live in beta, check it out!
Dyne Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dyne Therapeutics and similar public comparables like Jinyu Bio-Technology Co., Arcus Biosciences, Sinocelltech Group, Cosmo Pharmaceuticals and more.
Dyne Therapeutics Overview
About Dyne Therapeutics
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Founded
2017
HQ
Employees
191
Website
Sectors
Financials (LTM)
EV
$2B
Dyne Therapeutics Financials
Dyne Therapeutics reported last 12-month revenue of — and negative EBITDA of ($471M).
In the same LTM period, Dyne Therapeutics generated — in gross profit, ($471M) in EBITDA losses, and had net loss of ($460M).
Revenue (LTM)
Dyne Therapeutics P&L
In the most recent fiscal year, Dyne Therapeutics reported revenue of — and EBITDA of ($438M).
Dyne Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($471M) | XXX | ($438M) | XXX | XXX | XXX |
| Net Profit | ($460M) | XXX | ($446M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dyne Therapeutics Stock Performance
Dyne Therapeutics has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Dyne Therapeutics' stock price is $15.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 0.0% | XXX | XXX | XXX | $-2.71 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDyne Therapeutics Valuation Multiples
Dyne Therapeutics trades at (3.9x) EV/EBITDA.
Dyne Therapeutics Financial Valuation Multiples
As of March 23, 2026, Dyne Therapeutics has market cap of $3B and EV of $2B.
Equity research analysts estimate Dyne Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dyne Therapeutics has a P/E ratio of (5.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/EBITDA | (3.9x) | XXX | (4.2x) | XXX | XXX | XXX |
| EV/EBIT | (3.9x) | XXX | (4.0x) | XXX | XXX | XXX |
| P/E | (5.4x) | XXX | (5.6x) | XXX | XXX | XXX |
| EV/FCF | (4.1x) | XXX | (4.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dyne Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dyne Therapeutics Margins & Growth Rates
Dyne Therapeutics' revenue in the last fiscal year grew by —.
Dyne Therapeutics' revenue per employee in the last FY averaged $0.0M.
Dyne Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 14% | XXX | 20% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dyne Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Jinyu Bio-Technology Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcus Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocelltech Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Cosmo Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| D&D Pharmatech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dyne Therapeutics M&A Activity
Dyne Therapeutics acquired XXX companies to date.
Last acquisition by Dyne Therapeutics was on XXXXXXXX, XXXXX. Dyne Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dyne Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDyne Therapeutics Investment Activity
Dyne Therapeutics invested in XXX companies to date.
Dyne Therapeutics made its latest investment on XXXXXXXX, XXXXX. Dyne Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dyne Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dyne Therapeutics
| When was Dyne Therapeutics founded? | Dyne Therapeutics was founded in 2017. |
| Where is Dyne Therapeutics headquartered? | Dyne Therapeutics is headquartered in United States. |
| How many employees does Dyne Therapeutics have? | As of today, Dyne Therapeutics has over 191 employees. |
| Who is the CEO of Dyne Therapeutics? | Dyne Therapeutics' CEO is John G. Cox. |
| Is Dyne Therapeutics publicly listed? | Yes, Dyne Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Dyne Therapeutics? | Dyne Therapeutics trades under DYN ticker. |
| When did Dyne Therapeutics go public? | Dyne Therapeutics went public in 2020. |
| Who are competitors of Dyne Therapeutics? | Dyne Therapeutics main competitors are Jinyu Bio-Technology Co., Arcus Biosciences, Sinocelltech Group, Cosmo Pharmaceuticals. |
| What is the current market cap of Dyne Therapeutics? | Dyne Therapeutics' current market cap is $3B. |
| Is Dyne Therapeutics profitable? | No, Dyne Therapeutics is not profitable. |
| What is the current EBITDA of Dyne Therapeutics? | Dyne Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Dyne Therapeutics? | Current EBITDA multiple of Dyne Therapeutics is (3.9x). |
| What is the current FCF of Dyne Therapeutics? | Dyne Therapeutics' last 12 months FCF is ($445M). |
| What is the current EV/FCF multiple of Dyne Therapeutics? | Current FCF multiple of Dyne Therapeutics is (4.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.